Pemazyre (pemigatinib), a targeted therapy for biliary tract cancer supplied to Korea by Handok, has successfully received reimbursement standards from the Health Insurance Review and Assessment Service's Cancer Disease Review Committee (CDDC).

The reimbursement standards for the immuno-oncology drug Tevimbra were also set at the meeting. Merck's Erbitux has been granted an extended reimbursement.

The CDDC held a meeting on the 28th to review reimbursement for new anti-cancer drugs and extend reimbursement for listed drugs.

As a result, Handok’s Pemazyre may be reimbursed for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholang